Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Stock Report

Market Cap: US$2.9m

Biodexa Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Biodexa Pharmaceuticals has a total shareholder equity of £8.7M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £14.0M and £5.2M respectively.

Key information

0%

Debt to equity ratio

UK£0

Debt

Interest coverage ration/a
CashUK£5.06m
EquityUK£8.73m
Total liabilitiesUK£5.24m
Total assetsUK£13.97m

Recent financial health updates

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

Financial Position Analysis

Short Term Liabilities: BDRX's short term assets (£7.5M) exceed its short term liabilities (£3.5M).

Long Term Liabilities: BDRX's short term assets (£7.5M) exceed its long term liabilities (£1.8M).


Debt to Equity History and Analysis

Debt Level: BDRX is debt free.

Reducing Debt: BDRX has no debt compared to 5 years ago when its debt to equity ratio was 4.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BDRX has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: BDRX is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies